Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIB | P23284 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21950002 | 0.75 | MAPT (0.55) | NPC1MAPTRAB9ASMN1; SMN2HTR2A | |
| SCHEMBL18322062 | 0.71 | KCNH2 (0.42) | PPIBKDM4ENPC1ALDH1A1GAA | |
| SCHEMBL30237270 | 0.71 | KCNH2 (0.42) | PPIBKDM4ENPC1ALDH1A1GAA | |
| SCHEMBL4460348 | 0.70 | SMN1; SMN2 (0.48) | PPIBKDM4ENPC1ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL30236593 | 0.70 | KCNH2 (0.41) | PPIBKDM4ENPC1ALDH1A1GAA | |
| SCHEMBL409751 | 0.70 | MAOA (0.38) | ALDH1A1GAASMN1; SMN2SIGMAR1HTR2A | |
| SCHEMBL2009830 | 0.69 | HIF1A (0.52) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL31371794 | 0.68 | TSHR (0.52) | PPIBKDM4EALDH1A1ALOX12SMN1; SMN2 | |
| SCHEMBL30396392 | 0.68 | DRD2 (0.50) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL7028269 | 0.68 | KDM4E (0.45) | PPIBKDM4EALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511721-B1 | GUANIDINO PHENYLALANIN COMPOUNDS USED AS UROKINASE INHIBITORS | WILEX AG (DE) | 2009-07-01 | — | — | EP | claimed |
| EP-1373234-B1 | UROKINASE INHIBITORS | WILEX AG (DE) | 2008-02-13 | — | — | EP | claimed |
| US-6861435-B2 | Urokinase inhibitors | PENTAPHARM AG (CH) | 2005-03-01 | — | — | US | claimed |
| US-20040110831-A1 | Urokinase inhibitors | WILEX AG (DE) | 2004-06-10 | — | — | US | claimed |
| EP-1373234-A2 | UROKINASE INHIBITORS | Pentapharm AG (CH) | 2004-01-02 | — | — | EP | claimed |
| WO-2002074756-A2 | UROKINASE INHIBITORS | PENTAPHARM AG (CH) | 2002-09-26 | — | — | WO | claimed |
| US-9089532-B2 | Stable dosage form of phenylalanine derivatives | WILEX AG (DE) | 2015-07-28 | — | — | US | disclosed |
| EP-1799265-B1 | STABLE DOSING FORM OF PHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2010-09-08 | — | — | EP | disclosed |
| EP-1511721-B1 | GUANIDINO PHENYLALANIN COMPOUNDS USED AS UROKINASE INHIBITORS | WILEX AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-7538216-B2 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2009-05-26 | — | — | US | disclosed |
| US-7342018-B2 | Urokinase inhibitors and uses thereof | WILEX AG (DE) | 2008-03-11 | — | — | US | disclosed |
| EP-1373234-B1 | UROKINASE INHIBITORS | WILEX AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070244127-A1 | Stable Dosage Form of Phenylalanine Derivatives | WILEX AG (DE) | 2007-10-18 | — | — | US | disclosed |
| WO-2003103644-A2 | GUANIDINO PHENYLALANIN COMPOUNDS USED AS UROKINASE INHIBITORS | WILEX AG (DE) | 2003-12-18 | — | — | WO | disclosed |
| US-6624169-B1 | 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases targeting lymphocytes and for treating disorders of the lymphatic tissue, in particular lymphomas. | WILEX BIOTECHNOLOGY GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030013723-A1 | Antitumor agents | WILEX AG | 2003-01-16 | — | — | US | disclosed |
| EP-1264828-A1 | New inhibitor of urokinase | Wilex AG (DE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002074756-A2 | UROKINASE INHIBITORS | PENTAPHARM AG (CH) | 2002-09-26 | — | — | WO | disclosed |
| EP-1098651-A2 | NOVEL UROKINASE INHIBITORS | Wilex Biotechnology GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004954-A2 | NOVEL UROKINASE INHIBITORS | WILEX BIOTECHNOLOGY GMBH (DE) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244127-A1 | Stable Dosage Form of Phenylalanine Derivatives | FAP, PAH, PEPD | PPIB 602/4885KDM4E 1455/4885NPC1 3346/4885 |
| US-20030013723-A1 | Antitumor agents | DNPEP, PLAU, ENPEP | PPIB 3277/4885KDM4E 3747/4885NPC1 4231/4885 |
| US-20040110831-A1 | Urokinase inhibitors | RNASE1, PLAUR, PLAU | PPIB 3696/4885KDM4E 4244/4885NPC1 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.